Obesity candidate dropped but other progress for Shionogi pipeline
This article was originally published in Scrip
Executive Summary
Shionogi has finally decided to call time on its once big hope for obesity velneperit (S-2367), dropping the remaining Japanese development program for the first-in-class oral neuropeptide Y Y5 receptor antagonist at the Phase IIb stage.